Traded Aug 13, 2026 · Filed Aug 14, 2026
The boss of Johnson & Johnson sold $5.5M of Johnson & Johnson shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$5,495,712
Shares × reported transaction price
29 days after results of Jul 15, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $262.08 on Aug 13, 2026, within 2% of its 52-week high, after a 3% rise over the previous 30 trading days
52-week range $174.16 (Sep 18, 2025) to $267.24 (Jul 7, 2026), 94% of the way up, from 251 adjusted closes. 30 trading days earlier: $253.98 on Jul 1, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Imaavy on Aug 24, 2026, 11 days after this trade.
New use approved (efficacy supplement). Active ingredient: Nipocalimab-Aahu. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +4.1% | -1.2% | +5.3% |
| 30 days | +1.9% | -2.4% | +4.3% |
Past results only. Not a forecast.
Congress tradeSits on House Energy and Commerce4 different filers disclosed JNJ within 90 days. Disclosed 16 days after the transaction; reported as an official range, not an exact amount.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
